Nu-Med Plus (NUMD) Common Equity (2011 - 2026)

Nu-Med Plus has disclosed Common Equity across 16 years of filings, most recently posting $90.0 million for Q2 2026.

• In Q2 2026, Common Equity rose 36582.44% year-over-year to $90.0 million; the TTM figure through Jun 2026 stood at $90.0 million (up 36582.44% YoY), while the FY2025 annual figure was $90.0 million, up 41941.78% from the prior year.
• Common Equity came in at $90.0 million for Q2 2026 at Nu-Med Plus, roughly flat from $90.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $90.0 million in Q4 2025 to a low of -$270131.0 in Q3 2022.
• Average Common Equity over 5 years is $10.4 million, with a median of -$185864.0 recorded in 2024.
• Year-over-year, Common Equity plunged 14865.54% in 2022 and jumped 41941.78% in 2025.
• Over 5 years, Common Equity stood at -$63025.0 in 2022, then sank by 132.85% to -$146751.0 in 2023, then slumped by 46.57% to -$215096.0 in 2024, then jumped by 41941.78% to $90.0 million in 2025, then changed by 0.0% to $90.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $90.0 million in Q2 2026, $90.0 million in Q4 2025, and -$258660.0 in Q3 2025.